Loading
A phase 1/2 trial of Capecitabine, Trastuzumab, Pertuzumab and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor is a phase 1/2 interventional study registered as NCT07140393 by Jiangsu HengRui Medicine Co., Ltd., with 120 participants planned, started 2025-10-28 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4508+ Capecitabine, HRS-4508+ Trastuzumab, HRS-4508+ Trastuzumab+ Pertuzumab, HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel, HRS-4508+ Trastuzumab + Nab-paclitaxel and HRS-4508+ Trastuzumab+ Capecitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Pertuzumab, Jiangsu Hengrui Pharmaceuticals, Trastuzumab and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/